According to Royalty Pharma latest financial reports the cash on hand of RPRX is $1.23B, an decrease of -49.18% to 2022. At the end of 2022 company had $2.43B cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $1.23B | -49.18% |
2022 | $2.43B | -13.39% |
2021 | $2.80B | 5.82% |
2020 | $2.65B | 233.97% |
2019 | $793.21M | -66.76% |
2018 | $2.39B | - |